Nimbus Therapeutics CEO Jeb Keiper at #JPM24 (Brian Benton Photography)
May 23, 2024 05:00 PM EDT
R&D

Af­ter $4B Take­da deal, Nim­bus lays out ‘grand’ hopes for its next-gen im­munother­a­py drug

Andrew Dunn

Senior Biopharma Correspondent

Just over a year ago, Nim­bus Ther­a­peu­tics closed one of the biggest sin­gle-drug deals in biotech, sell­ing its TYK2 in­hibitor to Take­da …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

AI drug dis­cov­ery start­up goes pub­lic in Hong Kong, nab­bing $115M to build on phar­ma part­ner­ships

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times